Professional Documents
Culture Documents
http://www.mddionline.com/article/first-file-patent-rule-threatens-med...
Search
Home
News
Blog
Products
Events
MDEA
Qualified Suppliers
About
Resources
First Person
Printer-friendly version
The Leahy-Smith America Invents Act (AIA)the first significant amendment to the U.S. patent system in 60 yearsis causing anxiety and speculation in the medical device industry. The Act, which was signed into law in September 2011, went into full effect March 16. On that date, its most controversial aspect was enacted: patents will now be awarded to the first-to-file rather than to the first-to-invent individual, company, or other institution. The law was enacted to cure a variety of ills in the U.S. patent system, but its main objectives was to streamline the patent system, reduce patent litigation, and bolster innovation. The Act is a good, incremental step in these directions. But it also created unintended effects. The first-to-file rule already has corporations and smaller, medical device inventors concerned about two key issues: Expanded opposition procedures that will increase challenges to patents. The possible chilling effect on collaborations that are fueling a great deal of new product development in many industries. In the past, inventors could have years to develop and garner funding for patent filings. Now, under the Act, they will be forced to file patent applications quickly or risk losing claim to their inventions. This means the race to file likely will compromise every inventors ability to create high-quality and defensible patents. Large medical device makers will likely experience a deepening fear of divulging or receiving too much proprietary information when partnering with smaller entities and independent innovators. The result: an impact on the quantity and quality of new products developed in patent-driven and innovationcentric industries such as medical devices. For more than a decade, corporate America has been riding the trend of open innovation. These entities have opened themselves up to soliciting and receiving unsolicited ideas from people and organizations outside their own companies to stock new-product pipelines. And collaboration has increased substantially since the 2008 recession, when R&D budgets were slashed. In fact, companies that operate effective open innovation capabilities have by and large gained an advantage over their competitors. Unfortunately, the America Invents Act could greatly narrow the aperture of open innovation programs and limit the potential return that can be delivered to the company and, subsequently, the inventor. Unintentionally, the American Invents Act provides added motivation for all inventors to be vigilantly secretive regarding their innovation efforts to avoid tipping off another party that may then outrace them to a patent filing. The Act allows inventors to publish the details of their inventions up to one year before filing the patent application, protecting the invention for that time period. But there are significant drawbacks. By publishing before filing the patent application, the inventor loses the advantage of competitive stealth within the U.S., and forfeits ownership rights outside the U.S., given that most other countries consider published details of innovations as public domain. Additionally, publishing before filing may be viewed negatively by any companies considering a licensing or acquisition agreement because it may have given an early warning to competitors. U.S. corporations working with smaller organizations in an open innovation program will want them to operate in secret as much as possible. Larger firms might restrict their collaborators from publishing their inventions early or requiring them to accept very restrictive conditions before submitting ideas or innovations for consideration.
Most Recent
Most Viewed Top Rated Most Emailed
Stryker Sees Double Trouble from FDA CDRH Ombudsman Justifies Existence in Annual Report Maker of Prostate Cancer Screening Imaging Device Seeks $2.5 million First-to-File Patent Rule Threatens Medtech R&D Private-Public Partnership between FDA and Device Industry Kicks Off Inaugural Meeting Startup Treating Functional Mitral Valve Regurgitations Raises $2.4M FORNISEE lighted uterine manipulator system Sonicision cordless ultrasonic dissection system
Related articles
Roundtable: Medical Device Marketing Today Economies of Scale: Electronics Manufacturing Services Bring Balance Foster-Miller Has New Plan for Innovation SHS Invests in TNI Medical AG AAMI Board Gains Three Medtech Experts Siemens Warned by FDA on QSR Enhanced Imaging Reveals Brain’s Secrets The Program That Launched a Million Stents Release films designed for ceramic casting. Clinical Trials Standard Handed a Setback
1 of 2
04-04-2013 15:39
http://www.mddionline.com/article/first-file-patent-rule-threatens-med...
Overall, companies using a secure method of communicating disclosure-sensitive material will not only avoid the anxiety caused by the America Invents Act, but will also attract top innovators from around the globe for mutually beneficial collaborations.
White Papers
Device Industry
Supplier News Videos
Steve Berry is the chief development officer of e-Zassi LLC, a Fernandina Beach, FL-based provider of open innovation management software and solutions. Image courtesy of www.freeimages.co.uk
An Easier to Understand Guide to Design Control Requirements Energy Efficient Heat Sealing Equipment The Science Behind Donaldsons Odor-Adsorbing Ostomy Bag Filters Barcodes: Fast & Accurate Sample ID in the Lab Industry Spotlight
View More
No votes yet
For Advertisers | Privacy Policy | Contact | Subscribe | Sitemap 2013 UBM Canon
Related Sites from UBM Canon: - Qmed - Qualified Medical Suppliers - IVD Technology - European Medical Device Technology - Medical Product Manufacturing News - Medical Electronics Design - OrthoTec - China Medical Device Manufacturer - medtechinsider - medtechinsider auf Deutsch - Pharmaceutical & Medical Packaging News - Pharmalive
2 of 2
04-04-2013 15:39